The Centre for Global Vaccine Research

Working to develop and implement the use of vaccines against major infectious diseases.

Tel: +44 (0)151 795 9687

About the Centre

The Centre was an initiative built around successful international clinical vaccine research in Malawi, with leadership in the areas of rotavirus and pneumococcal vaccines. The work in the Centre has broadened out to a wide range of human and animal pathogens, making it one of the rare centres within the UK to promote the global prevention of vaccine-preventable diseases of both humans and animals.

Our Research Highlights

Zika Vaccine Development

Developing and trialing, in phase 1 studies, a vaccine to prevent zika infection. Based on a heterologous prime boost with different pox virus vectors to induce durable B and T cell responses against multiple viral antigens with a focus on use in pregnant women. 


AMR in Streptococcus pneumoniae is spread globally by a limited number of clones. PCV vaccination has decresed AMR among vaccine-type strains. AMR now emerges by expansion of non-PCV types. The project focuses on genetic/functional properties of AMR clones with the goal to target their success and transmission in the carrier population.

Rotavirus Vaccines

The study aims to investigate the different factors that can affect how effective rotavirus vaccine is in different children. In this study, the protection passed on from mothers to babies during pregnancy and after birth will be compared across Liverpool, India and Malawi. Additionally, the bacteria in the baby's stool from birth to the time of rotavirus vaccination will be used to investigate how the gut bacteria may be linked to better or worse responses to the rotavirus vaccine.

A New Generation of Pneumococcal Vaccine

The aim of this project is to design a novel vaccine for Pneumococcal Meningitis and Sepsis. The project will assess the efficacy and safety of the vaccine using clinically relevant in vivo models. Novel adjuvanted formulations will be combined with newly discovered pneumococcal antigens and evaluated for their broad and cross-stereotype cellular immune protection.